MONTREAL, April 19, 2007 (PRIME NEWSWIRE) -- Viropro Inc. (OTCBB:VPRO) ("Viropro") today provides an update to the financial community and to its shareholders regarding its March 19, 2007 announcement for the development of one of the company's main products, a targeted high volume sales Monoclonal Antibody.
"Step 1 of the seven-month development program with the Biotechnology Research Institute has been successfully completed. Monoclonal antibody genes have been inserted into our proprietary expression vectors, and the antibody has been shown to be properly produced into various cellular systems. The selection of initial stable high producing cell lines has begun. These preliminary results have been validated by an independent laboratory at Laval University, Quebec City," stated Dr. Jean-Marie Dupuy, President and CEO of Viropro. "The development program is going as originally planned and the selection of a set of high producing stable clones is in progress. This will allow Viropro to start-up the production process development phase," added Dr. Dupuy.
The company will then out-license this product to various biopharmaceutical manufacturing partners. Discussions to this effect are progressing well. Significant out-licensing revenues are expected starting in 2007.
About Viropro Inc.
Viropro Inc. conducts operations through its subsidiary Viropro International Inc., whose Head Office is located in Montreal, Canada. Viropro is a rapidly expanding biopharmaceutical company specializing in the transfer of its technologies for industrial production of biogeneric therapeutic proteins, excluding therapeutic vaccines, for the treatment of various diseases including cancer, diabetes, hepatitis or multiple sclerosis. The company's principal objective is to bring about the transfer of technology to pharmaceutical companies in emerging markets with unmet medical needs such as in South America, Asia and Africa. To expand its range of expertise in biopharmaceuticals excluding therapeutic vaccines, Viropro has concluded strategic alliances with various scientific and business partners renowned in national and international spheres. Viropro's business model rests on a strategy aimed at generating recurrent short and long-term revenues, all while maximizing the value of assets and profits of its shareholders.
For more information on Viropro Inc., please visit our website on www.viropro.com
Viropro Inc. Safe Harbor Statement
Except for any historic information contained herein, the matters discussed in this press release contain forward-looking statements that involve risks and uncertainties, which are subject to section 27A of the Securities Act of 1933 and section 21E of the Exchange Act of 1934, and are subject to safe harbor created by these sections. Any statements that express or involve discussions with respect to predictions, beliefs, plans, projections, objectives, goals, assumptions of future events or performances are not statements of historical fact and may be "forward-looking statements". Forward-looking statements in this release may be identified through the use of such words as "expects", "anticipates", "estimates", "believes", or statements indicating certain actions "may", "could", or "might" occur. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements, which involve numerous risks and uncertainties, including the Company's ability to market its products and services in a competitive environment as well as other factors.